{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:09:31Z","timestamp":1789754971856,"version":"4.0.1"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["5RO1AI143931"],"award-info":[{"award-number":["5RO1AI143931"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by progressive fibrosis and an increased risk of hepatocellular carcinoma (HCC). Recently, approved drug treatments for MASLD, including thyroid hormone receptor beta (THR-\u03b2) and glucagon-like peptide-1 (GLP-1) receptor agonists, have been effective in treating the underlying metabolic causes of MASLD. However, more effective and acute treatments, particularly for already advanced or cirrhotic steatohepatitis, remain elusive. Other drug candidates, such as cyclophilin inhibitors, which have shown promise for treating advanced MASLD, are still under investigation. Because advanced MASLD reflects both upstream metabolic stress and downstream, self-sustaining injury responses promoting inflammation and fibrogenesis, we investigated whether pairing GLP-1 agonism (metabolic correction) with cyclophilin inhibition (fibrosis and inflammation remodeling) would yield additive or emergent benefits. Thus, we evaluated Semaglutide, Rencofilstat (CRV431), and their co-administration in a C57BL\/6J model of diet- and toxin-induced MASLD via a Western diet, sucrose supplementation, and chronic carbon tetrachloride exposure. Semaglutide monotherapy significantly reduced body weight and decreased HCC burden (Kruskal-Wallis Analysis,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001) whereas fibrosis quantified by picrosirius red staining did not differ significantly across the treatment groups (Welch\u2019s Analysis of Variance,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.1725). Co-therapy did not improve collagen deposition compared with monotherapy. These findings indicate that the combination of GLP-1 receptor agonism with cyclophilin inhibition does not confer additive antifibrotic benefits in this advanced MASLD model, underscoring stage-dependent constraints on therapeutic synergy.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0358225","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:42:13Z","timestamp":1789753333000},"page":"e0358225","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Divergent effects of semaglutide and CRV431 Co-therapy on liver fibrosis and HCC in MASLD mouse model"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9015-4844","authenticated-orcid":true,"given":"Asha Z.","family":"Goodman","sequence":"first","affiliation":[{"name":"Scripps Research","place":["La Jolla, California, United States of America"],"department":["Department of Immunology & Microbiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston T.","family":"Stauffer","sequence":"additional","affiliation":[{"name":"Scripps Research","place":["La Jolla, California, United States of America"],"department":["Department of Immunology & Microbiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe A.","family":"Gallay","sequence":"additional","affiliation":[{"name":"Scripps Research","place":["La Jolla, California, United States of America"],"department":["Department of Immunology & Microbiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"issue":"3","key":"pone.0358225.ref001","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)","year":"2024","journal-title":"J Hepatol"},{"issue":"1","key":"pone.0358225.ref002","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"ZM Younossi","year":"2016","journal-title":"Hepatology"},{"key":"pone.0358225.ref003","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"MA Nauck","year":"2021","journal-title":"Mol Metab"},{"issue":"6","key":"pone.0358225.ref004","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2010.09.032","article-title":"Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase","volume":"54","author":"S Ben-Shlomo","year":"2011","journal-title":"J Hepatol"},{"key":"pone.0358225.ref005","doi-asserted-by":"crossref","first-page":"1417945","DOI":"10.3389\/fphar.2024.1417945","article-title":"Cyclophilin inhibition as a strategy for the treatment of human disease","volume":"15","author":"WT Stauffer","year":"2024","journal-title":"Front Pharmacol"},{"issue":"2","key":"pone.0358225.ref006","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1124\/jpet.119.261099","article-title":"A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models","volume":"371","author":"J Kuo","year":"2019","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"10","key":"pone.0358225.ref007","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.3390\/v15102099","article-title":"The Cyclophilin Inhibitor Rencofilstat Decreases HCV-Induced Hepatocellular Carcinoma Independently of Its Antiviral Activity","volume":"15","author":"W Stauffer","year":"2023","journal-title":"Viruses"},{"issue":"1","key":"pone.0358225.ref008","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3390\/ijms22010271","article-title":"Cyclophilin Inhibition Protects Against Experimental Acute Kidney Injury and Renal Interstitial Fibrosis","volume":"22","author":"KG Leong","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"pone.0358225.ref009","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.yjmcc.2012.03.004","article-title":"Cyclophilin A affects inflammation, virus elimination and myocardial fibrosis in coxsackievirus B3-induced myocarditis","volume":"53","author":"P Seizer","year":"2012","journal-title":"J Mol Cell Cardiol"},{"issue":"4","key":"pone.0358225.ref010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0301711","article-title":"Cyclophilin D knockout significantly prevents HCC development in a streptozotocin-induced mouse model of diabetes-linked NASH","volume":"19","author":"WT Stauffer","year":"2024","journal-title":"PLoS One"},{"issue":"3","key":"pone.0358225.ref011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0298211","article-title":"Mice lacking cyclophilin B, but not cyclophilin A, are protected from the development of NASH in a diet and chemical-induced model","volume":"19","author":"WT Stauffer","year":"2024","journal-title":"PLoS One"},{"issue":"7","key":"pone.0358225.ref012","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"SL Friedman","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"pone.0358225.ref013","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jhep.2018.03.011","article-title":"A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer","volume":"69","author":"T Tsuchida","year":"2018","journal-title":"J Hepatol"},{"issue":"4","key":"pone.0358225.ref014","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/hep.30626","article-title":"Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps","volume":"70","author":"A Lonardo","year":"2019","journal-title":"Hepatology"},{"key":"pone.0358225.ref015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/0023677215571192","article-title":"The carbon tetrachloride model in mice","volume":"49","author":"D Scholten","year":"2015","journal-title":"Lab Anim"},{"key":"pone.0358225.ref016","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3389\/fphar.2019.01129","article-title":"Cyclophilin Inhibitor NV556 Reduces Fibrosis and Hepatocellular Carcinoma Development in Mice With Non-Alcoholic Steatohepatitis","volume":"10","author":"J Kuo","year":"2019","journal-title":"Front Pharmacol"},{"issue":"7","key":"pone.0358225.ref017","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"J Schindelin","year":"2012","journal-title":"Nat Methods"},{"issue":"10","key":"pone.0358225.ref018","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.14309\/ajg.0000000000000388","article-title":"Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels","volume":"114","author":"S Gawrieh","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"pone.0358225.ref019","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1096\/fj.14-268425","article-title":"Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice","volume":"30","author":"SB Liu","year":"2016","journal-title":"FASEB J"},{"key":"pone.0358225.ref020","article-title":"Reversibility of liver fibrosis","volume":"39","author":"M Sun","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"pone.0358225.ref021","doi-asserted-by":"crossref","first-page":"112407","DOI":"10.1016\/j.diabres.2025.112407","article-title":"GLP-1 receptor agonists and risk of hepatocellular carcinoma and all-cause mortality in patients with MASLD and type 2 diabetes: a propensity score-matched population-based cohort study","volume":"227","author":"W-M Chen","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"pone.0358225.ref022","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/gutjnl-2023-330962","article-title":"Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes","volume":"73","author":"A Wester","year":"2024","journal-title":"Gut"},{"issue":"1","key":"pone.0358225.ref023","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12902-024-01775-2","article-title":"Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis","volume":"24","author":"M Shabil","year":"2024","journal-title":"BMC Endocr Disord"},{"key":"pone.0358225.ref024","doi-asserted-by":"crossref","first-page":"175397","DOI":"10.1016\/j.ejphar.2022.175397","article-title":"Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin","volume":"938","author":"SA Melander","year":"2023","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"pone.0358225.ref025","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.3390\/ijms25052961","article-title":"Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease","volume":"25","author":"M Soto-Catal\u00e1n","year":"2024","journal-title":"Int J Mol Sci"},{"key":"pone.0358225.ref026","doi-asserted-by":"crossref","first-page":"116271","DOI":"10.1016\/j.bcp.2024.116271","article-title":"Intracellular and extracellular Cyclophilin a promote cardiac fibrosis through TGF-\u03b2 signaling in response to angiotensin \u2161","volume":"225","author":"M Cao","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"pone.0358225.ref027","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bbrc.2022.01.059","article-title":"Liver cyclophilin D deficiency inhibits the progression of early NASH by ameliorating steatosis and inflammation","volume":"594","author":"X Li","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"issue":"19","key":"pone.0358225.ref028","doi-asserted-by":"crossref","first-page":"18558","DOI":"10.1074\/jbc.C500089200","article-title":"Properties of the permeability transition pore in mitochondria devoid of cyclophilin D","volume":"280","author":"E Basso","year":"2005","journal-title":"J Biol Chem"},{"issue":"1","key":"pone.0358225.ref029","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/cvr\/cvu035","article-title":"Cyclophilin A and EMMPRIN (CD147) in cardiovascular diseases","volume":"102","author":"P Seizer","year":"2014","journal-title":"Cardiovasc Res"},{"key":"pone.0358225.ref030","doi-asserted-by":"crossref","first-page":"1046130","DOI":"10.3389\/fendo.2022.1046130","article-title":"Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model","volume":"13","author":"S Niu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"pone.0358225.ref031","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1111\/jdi.70174","article-title":"Multi-pathway-driven hepatic protection: Semaglutide combined with HIIT counteracts diabetic liver injury in db\/db mice","volume":"16","author":"W Yu","year":"2025","journal-title":"J Diabetes Investig"},{"issue":"1","key":"pone.0358225.ref032","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41366-021-00955-7","article-title":"Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist","volume":"46","author":"RM Pontes-da-Silva","year":"2022","journal-title":"Int J Obes"},{"issue":"8","key":"pone.0358225.ref033","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.4049\/jimmunol.178.8.5288","article-title":"Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis","volume":"178","author":"JA Fallowfield","year":"2007","journal-title":"J Immunol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0358225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:42:19Z","timestamp":1789753339000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0358225"}},"subtitle":[],"editor":[{"given":"Farhadul","family":"Islam","sequence":"first","affiliation":[{"name":"University of Rajshahi","place":["BANGLADESH"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0358225","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]}}}